David W. Ollila
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
David W. Ollila has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
Dominic T. Moore
5 shared publicationsMichael O. Meyers
Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
5 shared publicationsCarolyn I. Sartor
Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
4 shared publicationsChad A. Livasy
Department of Pathology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
3 shared publicationsCherie M. Kuzmiak
Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
3 shared publicationsDag Pavic
Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
3 shared publications
Latest Publications
- Open Access
- 13 August 2026
- Published by Springer Nature in Clinical Epigenetics
- Vol. 18 (1)
EpiTIL: methylation tumor infiltrating lymphocyte (TIL) predictor associates with survival in primary melanoma
Background: Melanomas are immunogenic with significant variation of tumor infiltrating lymphocytes (TIL). Primary melanomas are routinely scored by pathologists, for TIL grade, as brisk, nonbrisk, and absent, but TIL grade is not utilized in staging. While brisk TIL grade predicts improved melanoma-specific survival, nonbrisk TIL grade often lacks prognostic significance. A high proportion of primary melanomas from stage II and III patients are scored as nonbrisk TIL grade. Our goal is to quantitatively predict T cell estimates in primary melanoma from DNA methylation data using immunofluorescence CD3 + staining as ground truth. Results: Primary cutaneous melanomas (n = 80), analyzed for multiplex-immunofluorescence (CD3, CD8, S100) and whole-genome DNA methylation, underwent elastic net modeling of the proportion of CD3 + T lymphocytes to build a quantitative prediction model for TILs in primary melanoma called EpiTIL. Melanoma-specific survival (MSS) Kaplan–Meier curves significantly differed by primary melanoma EpiTIL tertiles ( p = 0.001). Patients with intermediate or highest tertile EpiTIL scores had higher median probability of MSS than those with lowest tertile scores. EpiTIL added significant prognostic value for MSS beyond age, sex, and stage, analyzed using proportional hazard regression modelling ( p = 0.012). EpiTIL survival prediction was validated in two multi-omic studies, TCGA (n = 352) and InterMEL (n = 399). Among TCGA melanomas, the survival curves significantly differed by EpiTIL tertile scores ( p = 0.009) and EpiTIL scores added prognostic value to clinical factors ( p < 0.002). In the InterMEL case–control study of stage II/III melanoma, patients with 5-year MSS without recurrence (controls) had a significantly higher mean EpiTIL scores than those who died of melanoma within 5 years (cases) ( p = 1.5e − 11). Using logistic regression, EpiTIL scores significantly predicted 5-year MSS without recurrence, even after adjusting for age, sex, stage and TIL grade, with OR = 4.7 ( p = 2.38e-06) comparing the highest to lowest EpiTIL tertiles. Extending the EpiTIL prediction to the Newell metastatic melanoma cohort, we found immune checkpoint inhibitor responders had a significantly higher mean EpiTIL score than non-responders ( p = 0.047). Conclusion: EpiTIL is a DNA methylation-based predictor of T cell proportion that demonstrates potential prognostic value in primary melanoma, particularly for stages II and III. Furthermore, higher EpiTIL scores derived from primary melanomas were positively associated with improved therapeutic responses to immune checkpoint inhibitors in metastatic disease, highlighting its potential to identify patients most likely to benefit from immunotherapy.
- 13 August 2026
- Published by Springer Nature in Clinical Epigenetics
- Vol. 18 (1)
Open AccessEpiTIL: methylation tumor infiltrating lymphocyte (TIL) predictor associates with survival in primary melanoma
Background: Melanomas are immunogenic with significant variation of tumor infiltrating lymphocytes (TIL). Primary melanomas are routinely scored by pathologists, for TIL grade, as brisk, nonbrisk, and absent, but TIL grade is not utilized in staging. While brisk TIL grade predicts improved melanoma-specific survival, nonbrisk TIL grade often lacks prognostic significance. A high proportion of primary melanomas from stage II and III patients are scored as nonbrisk TIL grade. Our goal is to quantitatively predict T cell estimates in primary melanoma from DNA methylation data using immunofluorescence CD3 + staining as ground truth. Results: Primary cutaneous melanomas (n = 80), analyzed for multiplex-immunofluorescence (CD3, CD8, S100) and whole-genome DNA methylation, underwent elastic net modeling of the proportion of CD3 + T lymphocytes to build a quantitative prediction model for TILs in primary melanoma called EpiTIL. Melanoma-specific survival (MSS) Kaplan–Meier curves significantly differed by primary melanoma EpiTIL tertiles ( p = 0.001). Patients with intermediate or highest tertile EpiTIL scores had higher median probability of MSS than those with lowest tertile scores. EpiTIL added significant prognostic value for MSS beyond age, sex, and stage, analyzed using proportional hazard regression modelling ( p = 0.012). EpiTIL survival prediction was validated in two multi-omic studies, TCGA (n = 352) and InterMEL (n = 399). Among TCGA melanomas, the survival curves significantly differed by EpiTIL tertile scores ( p = 0.009) and EpiTIL scores added prognostic value to clinical factors ( p < 0.002). In the InterMEL case–control study of stage II/III melanoma, patients with 5-year MSS without recurrence (controls) had a significantly higher mean EpiTIL scores than those who died of melanoma within 5 years (cases) ( p = 1.5e − 11). Using logistic regression, EpiTIL scores significantly predicted 5-year MSS without recurrence, even after adjusting for age, sex, stage and TIL grade, with OR = 4.7 ( p = 2.38e-06) comparing the highest to lowest EpiTIL tertiles. Extending the EpiTIL prediction to the Newell metastatic melanoma cohort, we found immune checkpoint inhibitor responders had a significantly higher mean EpiTIL score than non-responders ( p = 0.047). Conclusion: EpiTIL is a DNA methylation-based predictor of T cell proportion that demonstrates potential prognostic value in primary melanoma, particularly for stages II and III. Furthermore, higher EpiTIL scores derived from primary melanomas were positively associated with improved therapeutic responses to immune checkpoint inhibitors in metastatic disease, highlighting its potential to identify patients most likely to benefit from immunotherapy.
- 15 March 2024
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 238 (4) , 508-516
Clinical and Histological Response to Talimogene Laherparepvec Therapy in Advanced Melanoma: Impact on Overall Survival
BACKGROUND: Talimogene laherparepvec (T-VEC) is an FDA-approved oncolytic herpesvirus therapy used for unresectable stage IIIB through IV metastatic melanoma. However, the correlation between clinical complete response (cCR) and pathologic complete response (pCR) in patients treated with T-VEC is understudied. STUDY DESIGN: We conducted a retrospective study from a prospectively maintained IRB-approved melanoma single-center database in patients treated with T-VEC from October 2015 to April 2022. Patients were categorized into 3 groups: cCR with pCR, cCR without pCR, and less than cCR. The primary endpoint was overall survival. We used descriptive statistics, chi-square tests, and Wilcoxon rank-sum tests to compare key covariates among exposure groups. We used survival analysis to compare survival curves and reported hazard ratio of death (95% CI) across exposure groups. RESULTS: We included 116 patients with a median overall survival (interquartile range) of 22.7 (14.8–39.3) months. The majority were men (69%) and White (97.4%), with a median age of 74.5 years. More than half of patients (n = 60, 51.6%) achieved cCR. Distribution among the groups was as follows: cCR with pCR (35.3%), cCR without pCR (16.3%), and less than cCR (48.4%). Median overall survival time (interquartile range) was 26.5 (18.6–36.0) months for cCR with pCR, 22.7 (14.4–35.5) months for cCR without pCR, and 17.8 (9.2–47.0) months for less than cCR (log-rank p value = 0.0033). CONCLUSIONS: Patients achieving cCR with pCR after T-VEC therapy have the most favorable overall survival outcomes, whereas those achieving cCR without pCR have inferior survival and those achieving less than cCR have the poorest overall survival outcomes. These findings emphasize the importance of histological confirmation and provide insights for optimizing T-VEC therapy in patients with advanced melanoma.
- 15 March 2024
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 238 (4) , 508-516
Clinical and Histological Response to Talimogene Laherparepvec Therapy in Advanced Melanoma: Impact on Overall Survival
BACKGROUND: Talimogene laherparepvec (T-VEC) is an FDA-approved oncolytic herpesvirus therapy used for unresectable stage IIIB through IV metastatic melanoma. However, the correlation between clinical complete response (cCR) and pathologic complete response (pCR) in patients treated with T-VEC is understudied. STUDY DESIGN: We conducted a retrospective study from a prospectively maintained IRB-approved melanoma single-center database in patients treated with T-VEC from October 2015 to April 2022. Patients were categorized into 3 groups: cCR with pCR, cCR without pCR, and less than cCR. The primary endpoint was overall survival. We used descriptive statistics, chi-square tests, and Wilcoxon rank-sum tests to compare key covariates among exposure groups. We used survival analysis to compare survival curves and reported hazard ratio of death (95% CI) across exposure groups. RESULTS: We included 116 patients with a median overall survival (interquartile range) of 22.7 (14.8–39.3) months. The majority were men (69%) and White (97.4%), with a median age of 74.5 years. More than half of patients (n = 60, 51.6%) achieved cCR. Distribution among the groups was as follows: cCR with pCR (35.3%), cCR without pCR (16.3%), and less than cCR (48.4%). Median overall survival time (interquartile range) was 26.5 (18.6–36.0) months for cCR with pCR, 22.7 (14.4–35.5) months for cCR without pCR, and 17.8 (9.2–47.0) months for less than cCR (log-rank p value = 0.0033). CONCLUSIONS: Patients achieving cCR with pCR after T-VEC therapy have the most favorable overall survival outcomes, whereas those achieving cCR without pCR have inferior survival and those achieving less than cCR have the poorest overall survival outcomes. These findings emphasize the importance of histological confirmation and provide insights for optimizing T-VEC therapy in patients with advanced melanoma.
- Open Access
Sex-Specific Associations of MDM2 and MDM4 Variants with Risk of Multiple Primary Melanomas and Melanoma Survival in Non-Hispanic Whites
MDM2-SNP309 (rs2279744), a common genetic modifier of cancer incidence in Li-Fraumeni syndrome, modifies risk, age of onset, or prognosis in a variety of cancers. Melanoma incidence and outcomes vary by sex, and although SNP309 exerts an effect on the estrogen receptor, no consensus exists on its effect on melanoma. MDM2 and MDM4 restrain p53-mediated tumor suppression, independently or together. We investigated SNP309, an a priori MDM4-rs4245739, and two coinherited variants, in a population-based cohort of 3663 primary incident melanomas. Per-allele and per-haplotype (MDM2_SNP309-SNP285; MDM4_rs4245739-rs1563828) odds ratios (OR) for multiple-melanoma were estimated with logistic regression models. Hazard ratios (HR) for melanoma death were estimated with Cox proportional hazards models. In analyses adjusted for covariates, females carrying MDM4-rs4245739*C were more likely to develop multiple melanomas (ORper-allele = 1.25, 95% CI 1.03–1.51, and Ptrend = 0.03), while MDM2-rs2279744*G was inversely associated with melanoma-death (HRper-allele = 0.63, 95% CI 0.42–0.95, and Ptrend = 0.03). We identified 16 coinherited expression quantitative loci that control the expression of MDM2, MDM4, and other genes in the skin, brain, and lungs. Our results suggest that MDM4/MDM2 variants are associated with the development of subsequent primaries and with the death of melanoma in a sex-dependent manner. Further investigations of the complex MDM2/MDM4 motif, and its contribution to the tumor microenvironment and observed associations, are warranted.
Open AccessSex-Specific Associations of MDM2 and MDM4 Variants with Risk of Multiple Primary Melanomas and Melanoma Survival in Non-Hispanic Whites
MDM2-SNP309 (rs2279744), a common genetic modifier of cancer incidence in Li-Fraumeni syndrome, modifies risk, age of onset, or prognosis in a variety of cancers. Melanoma incidence and outcomes vary by sex, and although SNP309 exerts an effect on the estrogen receptor, no consensus exists on its effect on melanoma. MDM2 and MDM4 restrain p53-mediated tumor suppression, independently or together. We investigated SNP309, an a priori MDM4-rs4245739, and two coinherited variants, in a population-based cohort of 3663 primary incident melanomas. Per-allele and per-haplotype (MDM2_SNP309-SNP285; MDM4_rs4245739-rs1563828) odds ratios (OR) for multiple-melanoma were estimated with logistic regression models. Hazard ratios (HR) for melanoma death were estimated with Cox proportional hazards models. In analyses adjusted for covariates, females carrying MDM4-rs4245739*C were more likely to develop multiple melanomas (ORper-allele = 1.25, 95% CI 1.03–1.51, and Ptrend = 0.03), while MDM2-rs2279744*G was inversely associated with melanoma-death (HRper-allele = 0.63, 95% CI 0.42–0.95, and Ptrend = 0.03). We identified 16 coinherited expression quantitative loci that control the expression of MDM2, MDM4, and other genes in the skin, brain, and lungs. Our results suggest that MDM4/MDM2 variants are associated with the development of subsequent primaries and with the death of melanoma in a sex-dependent manner. Further investigations of the complex MDM2/MDM4 motif, and its contribution to the tumor microenvironment and observed associations, are warranted.
- 19 January 2022
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 234 (4) , 538-545
Prospective Evaluation of Radar-Localized Reflector–Directed Targeted Axillary Dissection in Node-Positive Breast Cancer Patients after Neoadjuvant Systemic Therapy
Export BACKGROUND: This is a prospective, single-institution study to evaluate feasibility and accuracy of radar-localized reflector (RLR)–targeted axillary dissection (TAD) in node-positive breast cancer patients after neoadjuvant systemic therapy (NST). METHODS: Patients with biopsy-proven T1–2, N1–3 disease were eligible. Before NST, a marker clip and/or RLR was placed into the positive node. After NST, RLR was inserted if not placed previously. All patients underwent RLR TAD followed by axillary lymph node dissection (ALND). Primary end points of the trial were feasibility of RLR TAD and false negative rate (FNR). RESULTS: Between 2017 and 2021, 101 patients with N1–3 disease underwent NST. Five patients withdrew from the study, 1 was ineligible, and there were 9 technical failures, thus our final study cohort comprised 86 patients. RLR TAD was performed with probe guidance and confirmed with intraoperative specimen radiograph. After RLR TAD, ALND was performed. Median number of RLR TAD nodes removed was 2 (range 1–10), and the RLR TAD nodes remained positive in 56 patients. Median number of ALND nodes removed was 18 (range 4-46). Accounting for 9 technical failures, feasibility was 90%. All technical failures occurred with attempted placement of RLR after NST. Feasibility rate was 100% when RLR placement occurred at diagnosis. Of the evaluable 86 patients, RLR TAD accurately predicted axillary status in 83 patients, with FNR of 5.1%. CONCLUSION: We demonstrate high accuracy of RLR TAD, especially when RLR is placed before NST. For patients who present with N1–3 disease, this is another step towards axillary surgery de-escalation strategies.
- 19 January 2022
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 234 (4) , 538-545
Prospective Evaluation of Radar-Localized Reflector–Directed Targeted Axillary Dissection in Node-Positive Breast Cancer Patients after Neoadjuvant Systemic Therapy
Export BACKGROUND: This is a prospective, single-institution study to evaluate feasibility and accuracy of radar-localized reflector (RLR)–targeted axillary dissection (TAD) in node-positive breast cancer patients after neoadjuvant systemic therapy (NST). METHODS: Patients with biopsy-proven T1–2, N1–3 disease were eligible. Before NST, a marker clip and/or RLR was placed into the positive node. After NST, RLR was inserted if not placed previously. All patients underwent RLR TAD followed by axillary lymph node dissection (ALND). Primary end points of the trial were feasibility of RLR TAD and false negative rate (FNR). RESULTS: Between 2017 and 2021, 101 patients with N1–3 disease underwent NST. Five patients withdrew from the study, 1 was ineligible, and there were 9 technical failures, thus our final study cohort comprised 86 patients. RLR TAD was performed with probe guidance and confirmed with intraoperative specimen radiograph. After RLR TAD, ALND was performed. Median number of RLR TAD nodes removed was 2 (range 1–10), and the RLR TAD nodes remained positive in 56 patients. Median number of ALND nodes removed was 18 (range 4-46). Accounting for 9 technical failures, feasibility was 90%. All technical failures occurred with attempted placement of RLR after NST. Feasibility rate was 100% when RLR placement occurred at diagnosis. Of the evaluable 86 patients, RLR TAD accurately predicted axillary status in 83 patients, with FNR of 5.1%. CONCLUSION: We demonstrate high accuracy of RLR TAD, especially when RLR is placed before NST. For patients who present with N1–3 disease, this is another step towards axillary surgery de-escalation strategies.
- Open Access
- 16 November 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (6) , 4756-4771
Association of Melanoma-Risk Variants with Primary Melanoma Tumor Prognostic Characteristics and Melanoma-Specific Survival in the GEM Study
Genome-wide association studies (GWAS) and candidate pathway studies have identified low-penetrant genetic variants associated with cutaneous melanoma. We investigated the association of melanoma-risk variants with primary melanoma tumor prognostic characteristics and melanoma-specific survival. The Genes, Environment, and Melanoma Study enrolled 3285 European origin participants with incident invasive primary melanoma. For each of 47 melanoma-risk single nucleotide polymorphisms (SNPs), we used linear and logistic regression modeling to estimate, respectively, the per allele mean changes in log of Breslow thickness and odds ratios for presence of ulceration, mitoses, and tumor-infiltrating lymphocytes (TILs). We also used Cox proportional hazards regression modeling to estimate the per allele hazard ratios for melanoma-specific survival. Passing the false discovery threshold (p = 0.0026) were associations of IRF4 rs12203592 and CCND1 rs1485993 with log of Breslow thickness, and association of TERT rs2242652 with presence of mitoses. IRF4 rs12203592 also had nominal associations (p < 0.05) with presence of mitoses and melanoma-specific survival, as well as a borderline association (p = 0.07) with ulceration. CCND1 rs1485993 also had a borderline association with presence of mitoses (p = 0.06). MX2 rs45430 had nominal associations with log of Breslow thickness, presence of mitoses, and melanoma-specific survival. Our study indicates that further research investigating the associations of these genetic variants with underlying biologic pathways related to tumor progression is warranted.
- 16 November 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (6) , 4756-4771
Open AccessAssociation of Melanoma-Risk Variants with Primary Melanoma Tumor Prognostic Characteristics and Melanoma-Specific Survival in the GEM Study
Genome-wide association studies (GWAS) and candidate pathway studies have identified low-penetrant genetic variants associated with cutaneous melanoma. We investigated the association of melanoma-risk variants with primary melanoma tumor prognostic characteristics and melanoma-specific survival. The Genes, Environment, and Melanoma Study enrolled 3285 European origin participants with incident invasive primary melanoma. For each of 47 melanoma-risk single nucleotide polymorphisms (SNPs), we used linear and logistic regression modeling to estimate, respectively, the per allele mean changes in log of Breslow thickness and odds ratios for presence of ulceration, mitoses, and tumor-infiltrating lymphocytes (TILs). We also used Cox proportional hazards regression modeling to estimate the per allele hazard ratios for melanoma-specific survival. Passing the false discovery threshold (p = 0.0026) were associations of IRF4 rs12203592 and CCND1 rs1485993 with log of Breslow thickness, and association of TERT rs2242652 with presence of mitoses. IRF4 rs12203592 also had nominal associations (p < 0.05) with presence of mitoses and melanoma-specific survival, as well as a borderline association (p = 0.07) with ulceration. CCND1 rs1485993 also had a borderline association with presence of mitoses (p = 0.06). MX2 rs45430 had nominal associations with log of Breslow thickness, presence of mitoses, and melanoma-specific survival. Our study indicates that further research investigating the associations of these genetic variants with underlying biologic pathways related to tumor progression is warranted.
- 7 January 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (4) , 1916-1917
ASO Author Reflections: The Impact of Virtual Interviews for Complex General Surgical Oncology Fellowship
- 7 January 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (4) , 1916-1917
ASO Author Reflections: The Impact of Virtual Interviews for Complex General Surgical Oncology Fellowship
- Open Access
- 1 January 2021
- Published by OAE Publishing Inc.
- Vol. 5 (4) , 396-413
Talimogene laherparepvec and novel injectable oncolytic viruses in the management of metastatic melanoma
Journal of Translational Genetics and Genomics is an open access journal, publishing articles related to single gene disorders, rare genetic disease, specific genetic syndromes, complex disease, etc.
- 1 January 2021
- Published by OAE Publishing Inc.
- Vol. 5 (4) , 396-413
Open AccessTalimogene laherparepvec and novel injectable oncolytic viruses in the management of metastatic melanoma
Journal of Translational Genetics and Genomics is an open access journal, publishing articles related to single gene disorders, rare genetic disease, specific genetic syndromes, complex disease, etc.
- 12 December 2020
- Published by Springer Nature
- p. 151-166
The Role of PET/CT in Melanoma Patients: A Surgeon’s Perspective
- 12 December 2020
- Published by Springer Nature
- p. 151-166
The Role of PET/CT in Melanoma Patients: A Surgeon’s Perspective
- 26 November 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (4) , 1908-1915
Direct Comparison of In-Person Versus Virtual Interviews for Complex General Surgical Oncology Fellowship in the COVID-19 Era
In the era of coronavirus disease 2019 (COVID-19), many Complex General Surgical Oncology (CGSO) fellowship programs implemented virtual interviews (VI) du
- 26 November 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (4) , 1908-1915
Direct Comparison of In-Person Versus Virtual Interviews for Complex General Surgical Oncology Fellowship in the COVID-19 Era
In the era of coronavirus disease 2019 (COVID-19), many Complex General Surgical Oncology (CGSO) fellowship programs implemented virtual interviews (VI) du
- 1 September 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (9) , 3434-3435
ASO Author Reflections: More Isn't Always Best-Shaping the Dialogue to Decrease Overtreatment of the Axilla in the Elderly
- 1 September 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (9) , 3434-3435
ASO Author Reflections: More Isn't Always Best-Shaping the Dialogue to Decrease Overtreatment of the Axilla in the Elderly